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Ob~ves. ‘I&is study sougkt to determine the l-year clinical 
follow-up of patients iucluded in the Benesteot trial. 
Racw. The Benestent trial is a nmdomized study com- 
paring ekctlle Palmaz-Sekatz stent implautatioo with baIlooa 
angioplasty in patients with stable augina and a de aovo coronary 
arkry lesion. Seven-month bllow-up data have shown a decreased 
rate of resteaasis and fewer cliaifal events in tke steut group. It is 
not establisked wketber this favorable clhdcal auteome is maIn- 
taioed for longer periods or wketber cmunary steatiag defers 
restenosis and its subsqueut clioical manifestatbus. 
Mefhodv. To ckuify this oncednty, we updated clinical iofor- 
mation on all but I of 516 patients enrolled in tke Beuestent trial 
(257 in balloon group, 259 ia stent group) at least 12 ma&s after 
the intervention. Major clinical events (primary cliuical end 
point) were tabulated aeeordiug to tbe intention to treat priuciple 
and included de&, tke oeearreace of a cehvaxular accident, 
mytnxrdial in&r&u, the need for bypass surgery or a liuiber 
percutaneous intervention in the previously treated lesion. 
Results. After 1 year, uo significant dikreuces in mortality 
(1.2% vs. 0.8%), stroke (0.0% vs. 0.8%). myocardial infarction 
(5.0% vs. 4.2%) or eoroaary bypass graft surgery (6.9% vs. 5.1%) 
were found between tke stent aad ballooa aagioplasty groups, 
respectiveIy. However, tke requirement for a repeat angioplasty 
prwcedure was sigailicantly lower ia tbe steut group (10%) than 
tbe balloaa angbphsty group (2196, rehtive risk [RR] 0.49,95% 
coafMie.ace interval ICI] 031 ta 0.75, p = O.OOl), aud overall 
primary end points w less frequeatly reacked by stent group 
patients (23.2%) than those in the baMoon group (315%, RR 0.74, 
95% CI 055 to O.%, p = 0.64). No diiereaces were fouad between 
groups with respect to fi~octkmal class aagina and prescribed 
medIItioa at tke time of follow-up. 
ConeLLFiofis. Tkese clinical follow-up data show that UK benefit 
of elective aative conmary artery steating in patients with stable 
auginais-toatIeastlyearaflertbepbeedurraud 
resaltsiaasi@&aatlyrPdmdreqoirrareotfarrepeatintmeatia 
CJAm Cdl Gdid l!W6;27:2S-61) 
Despite considerable technical improvement in coronary 
balloon angioplasty, the restenosis process remains the 
major limitation of this interventional technique (l-3). 
Restenosis has been found to be unresponsive to a wide 
variety of drugs, diets and different balloon strategies (4). 
Consequently. new devices for transluminal revasculariza- 
t;on have been developed and tested in clinical practice with 
tne aim of reducing the incidence of restenosis (5-8). 
Iatracoronary stent implantation has proved to be successful 
in the treatment of coronary artery dissections and in 
preventing abrupt vessel closure (9,lO). Furthermore, it has 
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been suggested that stenting may improve long-term angio- 
graphic outcome by optimizing the immediate angiographic 
result (11.12). Recently, two major randomized studies 
comparing balloon angioplasty with elective coronary 
Paimaz-Schatz stenting in de novn lesions of patients ,with 
stable angina syndromes have been completed (13.14). Both 
studies have demonstrated a lower rate of restenosis 7 
months after the intervention in stented lesions. The Be- 
nestent trial has also shown a superior clinical outcome at 
‘7-month follow-up in those patients who received a stent 
(13). Despite this real benefit, the limitations of coronary 
stenting, such as h!eeding and vascular complications, sub- 
acute stent thrombosis and cost remain a concern for those 
considering stenting in their daily interventional practice. 
More important, the question of whether the stent is 
capable of reducing ..nd not merely delaying the restenotic 
process needs to be addressed (IS). To address this ques- 
tion, we assessed the I-year clinical outcome of the 516 
patients recruited in the Benestent trial. 
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Methods 
Stody patients. Patients with stable angina and a single 
new lesion of the native coronary circulation were included in 
the study. Angiographic criteria for enrollment included a 
target lesion 4.5 mm long, located in a vessel >3 mm in 
diameter and supplying normally functioning myocardium. 
Angiographic exclusion criteria included ostial and bifurcation 
lesions, evidence of intracoronary thrombus, previously grafted 
vessels and severe vessel tortuosity. Other clinical exclusion 
criteria were age ~30 or >75 years, contraindication to 
anticoagulant or antiplatelet therapy, ineligibility for coronaty 
bypass surgery and any surgical intervention planned for the 
following 6 months. After providing verbal or written informed 
consent, patients telephoned a central office and were ran- 
domly assigned to either stent implantation or balloon angio- 
plasty. Randomization was stratified according to center with 
blocks of six treatment assignments to ensure an equal distri- 
bution of treatments in each center. Clinical and angiographic 
characteristics of the study patients are shown in Table 1. 
Angioptasty procedure. Balloon angioplasty and stent im- 
plantation were performed according to standard clinical prac- 
tice (13). The articulated Palmaz-Schatz strnt (Johnson & 
Johnson Interventional Systems) was used. Details of design 
and placement technique of the Palmaz-Schatz coronary stent 
have previously been described (13,16). All patients received 
aspirin (250 to 500 mg daily) and dipyridamole (75 mg three 
times a day) at least from the day before to 6 months after 
intervention. Patients undergoing coronary stent implanta:ion 
were treated with a continuous infusion of dextran (1,000 ml 
over 6 to 8 h) and a 10,000-U bolus of unfractionated heparin 
at the commencement of the procedure. A heparin bolus was 
repeated hourly in the event of a prolonged procedure. The 
femoral sheaths were removed 6 to 8 h after the intervention. 
Oral anticoagulant therapy (warfarin) was started after shedth 
removal, and patients were kept on continuous intravenous 
heparin therapy (to maintain activated partial thromboplastin 
time between 60 and 90 s) for at least 36 h, until the 
prothrombin time had reached the therapeutic range (intema- 
tional normalized ratio 2.5 to 3.5). Warfarin therapy was 
continued for 3 months. Patients who underwent conventional 
balloon angioplasty received a 10,000-U bolus of unfraction- 
ated heparin followed by an additional bolus hourly if neces- 
sary. In addition, both treatment groups received calcium 
antagonists until hospital discharge, with further medical treat- 
ment left to the clinician’s judgment. 
CR&al follow-up. According to the original protocol, pa- 
tients were seen in the outpatient clinic 1,3 and 6 months after 
the procedure. An interview, physical examination and elec- 
trocardiography were performed. Exercise testing was per- 
formed immediately before the 6.month hollow-up coronary 
angiogram unless early restudy had been clinically indicated. 
One year after the procedure, clinical information was ob- 
tamed dire&y from the patient at the outpatient clinic, by 
telephone interview or from the referring physician. At this 
time, a questionnaire was completed and included the follow- 
Table 1. Baseline Clinical, Angiographic and Procedural 
Character&in of 516 Patients Included in lntention to 
Treat Analysis 
Charxterislic 
Angioplasty 
(n = 2.57) 
582 IO 
79r I3 
I71 f 9 
212 (82) 
124 (48) 
60 (23) 
16 (6) 
Age (Ye 
Weight (kg) 
Height (cm) 
Male gender 
Ever-smoked 
Current smoker 
Diabetes mellitus 
Previous conditwns 
MI 
CABG 
Angioplasty 
HypcrtenGon 
Hypercholesterolcmia 
Stroke 
Peripheral vascular disease 
Exertional angina (CCS class) 
1 
II 
111 
IV 
NOW 
Mixed 
Artery dilated 
RCA 
LAD 
LCU 
Type of iesion 
Concentric 
Multiple irregularities 
Occluded (TIM1 0 OT I) 
Calcified 
Length (mm) 
Thromhus after procedure 
Nominal size of stem or balloon (mm) 
Largest balloon size (mm) 
Total inflation time (6) 
stem 
(n = 259) 
57 It 9 
Is+ 11 
171 cl3 
207 (80) 
I19(46) 
62 (24) 
17 (7) 
48 (19) 52 (20) 
5 (2) 0 
8 (3) 5 (2) 
x0 (35) 80(31) 
95 (37) 89 w 
6 (2) 6 (2) 
8(3) 10 (4) 
y (4) 
75 (29) 
1w (.(I) 
20 (8) 
23 (9) 
89 (35) 
9 (3) 
82 (32) 
125 (48) 
16 (6) 
27 (10) 
89 W) 
72 (28) 
159 (62) 
26 (IO) 
60 w 
165 (64) 
34(13) 
IlR(4b) 
216) 
5 (21 
?7(1l) 
6.96 + 2.57 
10 (4) 
3.29 2 0.3x 
3.30 2 0.38 
399 2 3s9 
130 (50) 
16 (6) 
9 (3) 
29 (11) 
7.06 r 2.56 
3 (1) 
3.31 f 0.34 
3.40 c 0.40 
18a ? 178 
Data presented are from Set-toys et al. (13) and are mean value +- SD or 
number (76) of patients. C’ABG = coronary bypass graft surgery; CC’S = 
Canadian Cardiovascular Society: LAD = left anterior descending cornnary’ 
artery; LCx = left circumflex coronary artery; MI = myocardial infarctian; 
RCA = right coronary artery; TIM1 = Thrombolysis in Myocardial Infarction. 
ing information: occurrence and date of any primary clinical 
end point, angina status according to the Canadian Cardiovas- 
cular Society classification (17) and antianginal medication 
used. 
Primary clinical end points. The following clinical end 
points were included and ranked according to the most severe 
on the following scale: death, cerebrovascular accident, myo- 
cardial infarction, bypass surgery or a second percutaneous 
intervention involving the site of the previously treated lesion. 
All events were reviewed by the critical events committee, 
which was unaware of the treatment allocation. When, more 
than one clinical end point occurred in a patient, the event 
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occurring firs! :vas considered for survival analysis. All events 
were considered for composite analysis. 
All deaths were included for analysis regardless of cause. 
Cerebrovascular acciahrs occurring in patients receiving anti- 
coagulant therapy were considered to be intracranial hemor- 
rhages unless unequivocally demonstrated otherwise. A m)o- 
cardial irzfarction was diagnosed if new pathologic Q waves 
according to the Minnesota Code (18) or an increase in serum 
creatine kinase levels to more than twice the normal value 
together, with an increase in the myocardial isoenzyme levels, 
was demonstrated. &pass surgey was defined to include an 
emergency or elective bypass operation involving the previ. 
ously treated coronary segment. An entewncy 4~~s operation 
was defined as one that required immediate transfer of the 
patient fr,Dm the angioplasty suite to the operating room. 
Rescue stent implantation was defined as stent deployment in 
the event of a complete or critical reduction in coronary blood 
tlow (Thrombolysis in Myocardial Infarction [TIMI] grade 0 or 
I) after balloon angioplasty or a reduction in baseline flow by 
one grade of the TIM1 classification (LY). In all instances, 
prolonged balloon inflation was attempted before rescue stent- 
ing was considered. Rescue stenting is currently perceived as 
an integral part of angioplasty strategy, and only associated 
untoward clinical events were counted as primary end points. 
Second percutaneous intewntions were those involving the 
previously treated lesion. The initial intervention was consid- 
ered romplete when the guiding catheter was removed from 
the arterial sheath. The symptomatic indication for a second 
intervention was substantiated by electrocardiographic or scin- 
tigraphic evidence of myocardial ischemia, or both. Rewscu- 
iarization (surgical or percutaneous) involving other coronary 
artery sites was not considered a primary end point. 
Secondary clinical end points. Secondary end points were 
assessed at the time of follow-up regardless of occurrence of 
primary end points acd included functional angina class and 
antianginal medication taken at that time. 
Statistical analysis. The principal clinical analysis con- 
sisted of a single comparison between the two study grouFr 
(stent and balloon) with respect to primary clinical end points 
regardless of the time of event occurrence. This an;rlysis 
included all patients according to the intention to treat prin- 
ciple. The chi-square test with the Yates correction was used to 
compare proportions. Discrete variables are expressed as 
counts and percentages and were compared in terms of relative 
risks for stented lesions compared with balloon-dilated lesions, 
including 95% confidence intervals calculated by the method 
of Greenland and Robins (20). Event-free survival after stent 
placement or balloon angioplasty was determined by Kaplan- 
Meier techniques and displayed as survival curves. Comparison 
between curves was performed using the log-rank and Wil- 
coxon test. 
Results 
Baseline characteristics, procedural factors and immediate 
and 7-month clinical and angiographic follow-up results of the 
257 
Benestent study have previously been reported (13). There 
were no differences in baseline clinical and angiographic 
characteristics between the two study groups (Table I). Of the 
259 patients randomly assigned to receive a stent. the proce- 
dure was unsuccessful in IO (8 underwent bypass surgery. 2 
were treated medically), and 14 patients (5.4%) crossed over 
and were treated successfully by balloon angioplasty. Of the 
257 patients randomly assigned to balloon angioplasty, II 
(4.3%) croswd over and were treated successfully with the 
implantation of a stent, and 5 required bypass surgery. There- 
fore, the procedural success rates were 92.7% in patients 
randomly assigned to stent implantation and Yl.l% in patients 
assigned to balloon angioplasty, whereas the angiographic 
success rates were 96.9% in stented lesions and 98.1% in 
balloon dilated lesions. Analysis of clinical outcome was per- 
formed according to the intention to treat principle, comparing 
follow-up of the 259 patients randomly assigned to stent 
implantation with that of the 257 patients randomly assigned to 
balloon angioplasty. 
The ranking and total number of clinical events occurring in 
hospital are shown in Table 2. There were no differences in the 
incidence of any primary clinical event between the groups. 
and the composite rate for all in-hospital events was similar in 
both (16 events [6.2%] in the angioplasty group vs. 18 events 
[6.9%] in the stent group: relative risk [RR] 1.12. 9SQ 
confidence interval [CI] 0.58 to 2.14). Angiographically docu- 
mented stent thrombosis during the hospital stay occurred in 
3.5% of patients, an incidence similar to that of subacute vessel 
closure after balloon angioplasty (2.78). However. the inci- 
dence of bleeding and vascular complications was significantly 
higher after stent implantation than after balloon angioplasty 
(13.5%vs.?.l%,RR4.34.Y5%CI2.O5toY.l8,p=O.OOl).The 
mean (tSD) hospital stay was 8.5 2 6.8 days in the stent group 
and significantly lower at 3.1 t 3.3 days in the angioplasty 
group (p = 0.001). 
After 7 months of follow-up, P primary clinical end point 
was reached by 76 (29.6%) of the 257 patients randomly 
assigned to balloon and by 52 (20.1%) of the 259 assigned to 
stent implantation (RR 0.68. 95% CI 0.50 to 0.92. p = 0.02). 
The need far a repeat angioplasty involving the target lesion 
was twofold higher in the balloon group than in the stent group 
(53 patients [20.6%] vs. 26 patients [lo%], respectively; RR 
0.49,95% Cl 0.31 tc 9.75, p = 0.001). In accordance with these 
clinic-l data, the minimal lumen diameter at angiographic 
follow-up was greater after stent implantation than after 
balloon angioplasty (1.82 2 0.64 vs. 1.73 ? 0.55 mm, p = 0.09, 
median dirference 0.17 mm), and the incidence of restenosis at 
7 months, according to the >50% stenosis criterion, was 22% 
after stent ‘-nplantation compared to 324, after balloon angio- 
plasty (p = 0.02). 
One-year follow-up. One year after the initial intervention, 
clinical follow-up information was available in all but one 
patient from the stent group (99.8%). The mean follow-up 
period was 12 months (range 03 to 34). All interviews were 
performed at least I year after the intervention unless the 
patient had died in the intervening period. In 169 patients 
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Table 2 Frequency of Primary Clinical End Points In-Hospital and 
at 7 Months and 1 Year in Descending Order of Severity and 
Followed by Total Number of Events 
pts with a clinical endpoint (?4)  
Event 
AOgiOplaS~ 
(n = 257) 
sent 
(n = 259) 
Relative Risk 
(95% CI) 
Death 
In-hospital 
At7mo 
At 1 yr 
All events 
CVA 
In-hospital 
At7mo 
At I yr 
All events 
Q wave MI 
In-hospital 
At'litto 
At I yr 
A8 events 
Non-Q wave MI 
In-hospital 
At7mo 
At I yr 
All events 
Urgent CABG 
in-hospital 
At7mo 
At lyr 
AU events 
Elective CABG 
In-hospital 
At7mo 
At 1 yr 
All events 
Repeat PTCA 
In-hospital 
At7mo 
At 1 yt 
AII events 
Any event 
In-hospital 
At7mo 
.QlYr 
All events 
0 
l(O.4) 
2(0.8) 
2(0.8) 
0 
2(0.8) 
3(1.2) 
3(1.2) 
1 (0.4) 
2(0.8) 
2(0.8) 
210.8) 
2 (0.8) 
4(1.6) 
5 (1.9) 
6(2.3) 
5 (1.9) 
l(2.7) 
9(3.5) 
10 (3.9) 
6(2.3) 
6(2.3) 
6(2.3) 
7(2.7) 
4 (1.5) 
4(1.5) 
4(1.5) 
4(1.5) 
4(1.6) 
4(1.6) 
4(1.6) 
5 (1.9) 
5(1.9) 
5(1.9) 
5(1.9) 
6(2.3) 
0 
6(2.3) 
9(3.5) 
lO(3.9) 
3(1.2) 
S(3.1) 
13(5.0) 
15 (5.8) 
3 (1.2) 
53 (20.6) 
53 (20.6) 
69(26.8) 
1 (0.4) 
26 (10.0) 
26(10.0) 
45y.8) 
16(6.2) 
76(29.6) 
Sl(31.5) 
lS(6.9) 
52(20.1) 
60 (23.2) 
100 (38.9) 83(32.0) 
- 
1.98(0.18-21.75) 
1.49(0.25-8.83) 
1.49(0.25-8.83) 
- 
- 
- 
- 
2.48(0.49-32.67) 
I.74(0.51-5.86) 
1.79(0.61-5.26) 
1.65 (0.61-4.40) 
0.66(0.19-2.32) 
0.66(0.19-2.32) 
0.66(0.19-2.32) 
0.57 (0.17-1.91) 
1.24(0X-4.57) 
1.24(0.34-4.57) 
1.24 (0.34-4.57) 
1.19(0.37-3.05) 
- 
1.32(0.47-3.76) 
1.43(0.62-3.29) 
1.49(0&i-3.25) 
0.33(0.03-3.16) 
0.49(0.32-0.75) 
0.49(0.31-0.75) 
0.65 (0.46-0.90) 
1.12(0.58-2.14) 
0.68(0.50-0.92) 
0.74(0.55-0.98) 
0.82(0.65-1.04) 
AI1 events = nonhierarchic listing of events at 1 year (e.g.. if a patient 
required repeat angioplasty and later coronary artety bypass graft surgety 
[CABG], the total taunt at 1 year would reflect both events, not just the worst 
event that occurred); Cl = confidence interval; CVA = aerehmvascular acci- 
dent; Ml = myocardial infarction; I’KA = percutaneous transluminal coronary 
angtoplas~ - = not applicable. 
(33%), information was obtained directly by, interview, by 
telephone in 256 (50%) and from the referring physician in the 
remaining 87 (17%). After 1 year of follow-up, 176 patients 
(685%) assigned to balloon angioplasty and 199 (76.8%) 
assigned to stent implantation were free of clinical events (p < 
0.04). The difference in long-term clinical outcome is displayed 
in the cumulative distribution curves for the primary clinical 
end points in both treatment groups in Figure 1. When repeat 
Figure 1. Cumulative frequency distribution cutve for the two study 
groups showing percent of patients with primary clinical end points at 
foliow-ttp. Signiticant differences in the incidence of major clinical 
events appearing in the first 6 months are maintained at l-year 
f?ilOW-up. 
intervetttion was removed as a primary clinical end point, there 
was no significant difference in l-year event-free survival (87% 
for stent group, 89% for balloon group). Ranking for primary 
events and the total count of events at 1 year of follow-up are 
presented in Table 2. A primary clinical end point occurred in 
81 (32%) of the 257 patients randomly assigned to balloon 
angioplasty and in 60 (23%) of the 259 randomly assigned (0 
stent implantation (RR 0.74, 95% CI 0.55 to 0.98, p = 0.04). 
The most striking difference in clinical outcome between the 
balloon and stent groups was a significantly reduced require- 
ment for a further percutaneous intenention to the target 
lesion in the latter group (21% vs. IO%, respectively, RR 0.49, 
95% CI 0.31 to 0.75, p = 0.001). The distribution of angina 
class at the time of follow-up was similar in both groups, with 
86% of patients in the balloon group and 82% in the stem 
group remaining angina-free (Table 3). Antianginal medica- 
tion taken at the time of follow-up was similar in both groups 
(calcium antagonists 46% vs. 37%, beta-adrenergic blocking 
agents 31% vs. 25%, nitrates 16% vs. 13% and aspirin 88% vs. 
91%, for the balloon and stent group patients, respectively). 
However, as we have shown, those patients who underwent 
balloon angioplasty required a repeat interventional procedure 
more frequently to remain symptom-free. 
One-year status of patients event&e at 7.month follow- 
up. Primary clinical end points occurring after the 7-month 
follow-up assessment were rare. Of the 388 patients free of a 
primary event al 7-month follow-up, only 12 (3%) had a 
primary clinical event in the subsequent follow-up period. 
Table 3. Function&Class 1 Year After Intervention for 516 Patients 
Included in Intention to Treat Artalvsis 
CC3 Functional 
ClasS 
No angina 
I 
II 
111 
IV 
Unknown 
Angioplasty 
(n = 257) 
218(86) 
6 (2) 
23(9) 
8(3) 
0 (0) 
0 (0) 
Stent 
(n = 259) 
210(Q) 
16 (6) 
23 (9) 
4(2) 
0 (0) 
3(l) 
Data ate presented as number (95) of patients. CCS = Canadian Cardio- 
vascular Society. 
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Table 4. Clinical and Angiographic Characteristics of Patients Who Developed a First Clinical Event 
After 7 Months of Follow-Up 
- 
PI No./ Minimal Lumen Diameter (mm) 
Age W) S/B Primary Event Time (mo) east FUP D’S% FUP 
l/48 B PTCA 7 1.91 1.22 57 
2lhl s R-CA 8 2.23 0.99 hu 
3ihS S c.4BG x 2.93 1.37 50 
4rn S Q wave MI 8 2.53 2.oh 34 
5155 S PTCA 9 2.23 I.41 Sh 
664 S RCA 11 2.30 2.77 II 
7150 S Ml 12 2.63 2.31 27 
W70 S CABG 13 1.96 1.17 51 
9161 B CABG 16 2.(15 2.12 21 
IO/65 S Q wave MI 17 1.43 2.29 31 
Death 17 
1 l/59 B MI 21 2.41 2.3.4 49 
CABG 22 
1257 B FTCA 25 I.82 1.68 31 
B = halloon; S = stent; DS = diameter stenosis; FUP = follow-up; Pent = after procedure; Pt = patient: Time = 
from intetventi~,nal procedure IO primary clinical event. 
2.59 
Clinical and angiographic characteristics of these 12 patients 
are shown in Table 4. Of these patients, eight had undergone 
primary coronary stenting, and four a balloon angioplasty. The 
most frequent late clinical event was a rr+ascularization pro- 
cedure involving the target lesion (five repeat angioplasty, 
three bypass grafting). Additionally, there were three myocar- 
dial infarctions and one death. This s,;rall number of patients 
presenting with late clinical events does :rot permit a meaning- 
ful comparison between groups. However, five of the eight late 
revascularization procedures were perfcumed between 7 and 
11 months of follow-up, and four of taese. five patients ha, 
already developed angiographic restenosis at 7-month follow- 
up. 
Discussion 
The present review of the 516 patients enrolled in the 
Benestent trial, where patients with stable angina were ran- 
domized to stent implantation or balloon angioplasty for the 
treatment of new coronary lesions, demonstrates that the 
superior clinical outcome observed at 7-month follow-up in 
patients who received a stent is maintained to at least 1 year 
after the intervention with a low incidence of new clinical 
events. 
Clmical outcome in balloon and stent groups. The supe- 
rior clinical outcome of patients who underwent stent implan- 
tation is supported by the larger minimal lumen diameter 
documented at Fmonth follow-up with a subsequent reduction 
in clinically significant restenosis (13). However, it has been 
suggested (15) that the stent, a permanent metallic implant 
incorporated into the vessel wall, could prolong the time 
course over which intimal hyperplasia occurs and therefore. 
delay the appearance of restenosis to beyond the traditionally 
accepted period of 6 months. The results of our study show 
that the benefits obtained from stent implantation in the first 7 
months are maintained at least to beyond the first year of 
follow-up, with no further increase in late (~7 months) 
prima2 events in stem group patients compared with balloon 
group patients. There is thus no evidence to suggest a delay in 
the restenosis process. It has been argued (21-23) that clinical 
events occurring 1 year after coronary interventions may 
most likely be related to the natural progression of athero- 
sclerotic disease rather than to a delayed restenotic response 
to angioplasty-mediated arterial injury. Long-term angio- 
graphic follow-up studies (23) have shown a very low incidence 
(3%) of late stenosis at exactly the same site of previously 
dilated coronary segments in patients with a second coronary 
angiogram because of a recurrence of symptoms (23). 
Our results are also supported by nonrandomixed angio- 
graphic late follow-up studies (24-26). Clinical events in the 
300 stent group patients included death in 0.71, myocardial 
infarction in 3.7%, bypass grafting in 8% and repeat angio- 
plasty in 13%. Eighty percent of stent group patients were free 
of an adverse event (24). In addition, follow-up data for the 
National Heart Lung and Blood Institute-funded New Ap- 
proaches in Coronary Intervention registry are being collected. 
However, the lack of a comparison group of patients with 
similar lesions treated by conventional balloon angioplasty 
remains an important limitation of this type of regisby (25). 
Kimura et al. (26) reported a sign&u@ smaller vessel 
diameter at 6 months than immediately after stenting in 177 
patients (2.96 2 0.41 vs. 2.32 -C 0.51 mm, respectively, p = 
0.001). with no further decline in minimal lumen diameter 
between the 6 and 1Zmonth follow-up angiogram (2.32 f 
0.51 vs 2.30 ? 0.54 mm, respectively, p = NS). Late rester&s 
was documented in only four lesions (2.3%). Additionally, a 
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recent preliminary report from this group (27) and that of 
Foley et al. (28) have shown a significant late increase in 
minimal lumen diameter 2 to 3 years after Palmaz-Schatz 
coronary stenting, suggesting favorable wall remodeling of 
these stented segments. 
Early (4 months) versus late (>7 months) clinical out- 
come. The occurrence of a first primary end point beyond 7 
months after the procedure was very low in our study patients 
(2.3%), and although the small number of patients does not 
allow statistical comparison, it is of interest that most late 
events were revascularization procedures involving the target 
lesion (eight events) and that most revascularization proce- 
dures were performed close to the ‘I-month follow-up time in 
patients who had already developed restenosis at the time of 
angiographic follow-up (five events), suggesting that these 
“early” late events were in fact a consequence of a restenosis 
developing in the initial 7 months of follow-up. We suggest that 
by 7 months the adverse processes related to stent implanta- 
tion, namely thrombotic occlusion and iutimal hyperplasia, 
have become manifest, and late clinical events are more likely 
to be related to the natural progression of the underlying 
atherosclerotic disease than to the device used at the time of 
coronary angioplasty. 
When we exclude further coronary angioplasty as a major 
complication, an event that can be argued is a more benign 
complication than death, stroke, myocardial infarction or 
bypass surgery. we observe no significant difference in l-year 
outcome in the two treatment groups. However, it should not 
be forgotten that the coronary angioplasty procedure retains a 
small risk of mortality and morbidity. Additionally, there is a 
significant psychosocial impact on the patient and his or her 
family with every hospital admission, albeit for a “benign” 
procedure. The economic benefit of stenting will be investi- 
gated prospectively in the Benestent Ii study. It has been 
suggested that the cost of the stent, which, without doubt. 
impacts significantly on the cost of the stenting procedure, 
compared with balloon angioplasty. will diminish as competi- 
tion for the stent market increases. 
Clinical impkations and conclusions. The excellent long- 
term survival after’elective percutaneous interventions in our 
study is not surprising because most patients had single-vessel 
disease and good left ventricular function, features known to 
be associated with an excellent long-term prognosis. Coronary 
angioplasty has been demonstrated (29) to be more successful 
in relieving angina pecteris and improving exercise tolerance 
than medical treatment in patients with stable single-vessel 
coronary artery disease. However, the results of angioplasty 
are hampered by a high incidence of restenosis (30% to 40%) 
after an initially successful ball,mn dilrtion (30). Elective 
coronary stenting has been shown to improve the clinical and 
angiographic results of coronary angioplasty (13,14). However, 
these benefits are partially negated by the cost related to the 
stent itself, bleeding complications and a prolonged hospital 
stay (31,32). We eagerly await the results of trials of new stent 
designs, deployment strate@s and adjuvant therapies in an 
attempt to reduce or abolish these nondesirable effects (33,34). 
The maintenance of the clinical benefit achieved by elective 
coronary stenting resulting in a diminished need for repeat 
procedures may help to balance the cost/benefit equation of 
this new interventional strategy. 
Appendix 
Principal Investigators and Participuting Institutions 
for the Bencstent Trial 
Spain: Cor/o.r Macccyu. MD. University Hospital San Carlos. Madrid. 
The Netherlands: Putrick R Semtw, MD, Perer &or& MD. Mutie-An& 
Morel, MS<. University Hospital Rotterdam. Dijkzigt, Thorax Cutter, Rotter- 
dam: ticmy Sunuprunur~, MD, Zickenhuis de Weencnlanden. Zwolle: Gus Most. 
MD. St. Anto& Ziekenhuis, Nieuwegein; Peru &I He&r. MD. Academiseh 
Ziekenhuis. Groningcn: .&we/ Kwh. MD, Acadcmiach Medisch Ccntrum, Am- 
rterdam; Huns Ronnirr, MD, Catharina Ziekenhuis, Eindhoven. 
Italy: S/G Klugmann. MD, Hospital Ma&w, Trieste. 
Switzerland: Phillipe Urbur, MD. Hdpital C’antonal Universitaire. Geneva. 
Germany: ftudip Simon. MD, Christian Albrechts University. Kiel. 
France: Marie-Cloade Mwice, MD, Centre Cardiologique da Nord. Paris: 
Nicolu.? Danchin, MD, CHUR, Nancy; Claude Bormloonrr, MD. Polyclinique 
Volney. Rennes. 
Irelandz Pcfcr Cmsr, MD, James Hospital, Dublin. 
Belgium: WiNiam IQJn.~, MD. Cliniqucs Univerritaire\ St. Luc, University 
Catholique de Louvain, Brusxls. 
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